Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 8/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | CCR9 | P51686 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676833 | 0.87 | NOS3 (0.45) | NOS3NOS2MTORPIK3CAALOX5AP | |
| SCHEMBL29739395 | 0.87 | NOS3 (0.45) | NOS3NOS2MTORPIK3CAALOX5AP | |
| SCHEMBL23713770 | 0.82 | NOS3 (0.41) | NOS3NOS2MTORPIK3CAALOX5AP | |
| SCHEMBL16679436 | 0.79 | CCR9 (0.36) | CCR9MAPK1 | |
| SCHEMBL17055342 | 0.79 | OGA (0.40) | NOS3NOS2MTORPIK3CAPIK3R1 | |
| SCHEMBL29239380 | 0.79 | CCR9 (0.40) | CCR9ALOX5APMAP4K4 | |
| SCHEMBL16357120 | 0.76 | ALDH1A1 (0.42) | CCR9KDM4EL3MBTL1 | |
| SCHEMBL20489665 | 0.76 | CYP11B2 (0.37) | MTORPIK3CAPIK3R1ALOX5APMAP4K4 | |
| SCHEMBL16679707 | 0.73 | HTT (0.43) | MTORPIK3CAPIK3R1CCR9MAPK1 | |
| SCHEMBL24746458 | 0.72 | NOS3 (0.35) | NOS3NOS2MTORPIK3CAALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10188649-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| US-10188649-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2019-01-29 | — | — | US | disclosed |
| EP-3063143-B1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-05-16 | — | — | EP | disclosed |
| EP-3063143-B1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-05-16 | — | — | EP | disclosed |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-02-01 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| EP-3063143-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242996-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | US | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
| WO-2015066188-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247392-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | NOS3 1023/4885NOS2 846/4885MTOR 66/4885 |
| US-20150126490-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | NOS3 1023/4885NOS2 846/4885MTOR 66/4885 |
| US-10188649-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | NOS3 1023/4885NOS2 846/4885MTOR 66/4885 |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | NOS3 1023/4885NOS2 846/4885MTOR 66/4885 |
| US-20170182038-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | NOS3 1023/4885NOS2 846/4885MTOR 66/4885 |
| US-20180028532-A1 | AMINOHETEROARYL BENZAMIDES AS KINASE INHIBITORS | ABL1, MAP3K12, MAP3K2 | NOS3 1023/4885NOS2 846/4885MTOR 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.